Health Catalyst officer proposes $42.2K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Health Catalyst, Inc. officer Benjamin Landry reported a proposed sale of 29,478 common shares, with an aggregate market value of $42,153.54 and an approximate sale date of November 12, 2026. The shares were acquired upon vesting of restricted stock units between February 25 and September 1, 2026. The notice gives August 12, 2026 as the Rule 10b5-1 plan adoption or instruction date. Benjamin Landry's reported 10b5-1 sales also include 70,000 shares for gross proceeds of $100,023.00 on November 11, 2026, and 13,167 shares for $22,431.30 on September 1, 2026.
Key Figures
Key Terms
restricted stock units financial
Rule 10b5-1 regulatory
Aggregate Market Value financial
Gross Proceeds financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Benjamin Landry's recent HCAT sales?
AI-generated analysis. How Rhea-AI works. Not financial advice.